AG
AKBA icon

Aperio Group’s Akebia Therapeutics AKBA Stock Holding History

Aperio Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$61K Sell
21,953
-88
-0.4% -$257 ﹤0.01% 2401
2020
Q3 		$55K Buy
22,041
+481
+2% +$4.22K ﹤0.01% 2352
2020
Q2 		$293K Buy
21,560
+3,329
+18% +$34.4K ﹤0.01% 2036
2020
Q1 		$138K Buy
18,231
+7,863
+76% +$61.2K ﹤0.01% 2162
2019
Q4 		$66K Sell
10,368
-4,015
-28% -$19.1K ﹤0.01% 2288
2019
Q3 		$56K Buy
14,383
+7,901
+122% +$33.9K ﹤0.01% 2277
2019
Q2 		$31K Buy
+6,482
New +$36.9K ﹤0.01% 2618

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Aperio Group's AKBA Position: Q4 2020 in Review

Aperio Group reduced its Akebia Therapeutics (AKBA) stake by 0.4% in Q4 2020, selling an estimated $257 and leaving 21,953 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #2401.

Aperio Group first reported a position in AKBA in Q2 2019 and has held it in 7 quarters since. The position peaked at $293K in Q2 2020. 143 funds tracked by Wall St. Rank hold AKBA as of Q4 2020.

  • Aperio Group held 21,953 shares of Akebia Therapeutics worth $61K as of Q4 2020.
  • Aperio Group sold 88 Akebia Therapeutics shares in Q4 2020, an estimated $257.
  • Akebia Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2401 holding.
  • Aperio Group first reported a position in Akebia Therapeutics in Q2 2019 and has held it in 7 quarters since.
  • Aperio Group's Akebia Therapeutics position peaked at $293K in Q2 2020.
  • 143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.